Sensory Rehabilitation in Chemotherapy Induced Peripheral Neuropathy (CIPN)

Launched by ASSAF-HAROFEH MEDICAL CENTER · May 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a type of therapy called sensory rehabilitation for people who have developed nerve pain and other sensory issues after chemotherapy, a condition known as chemotherapy-induced peripheral neuropathy (CIPN). The aim is to see how effective this therapy is in helping patients manage their symptoms and improve their quality of life. The trial is currently looking for participants aged 18 and older who have experienced CIPN for more than three months after finishing chemotherapy.

To join the study, participants must not have had any nerve damage before starting chemotherapy, and they should not have had frequent falls or major issues with their legs before treatment. Those who are fluent in Hebrew will be able to participate since the assessments and treatments will be conducted in that language. If you decide to take part in this trial, you can expect to answer some questions about your symptoms and participate in physiotherapy sessions aimed at improving your sensory function. This could be a valuable opportunity to help yourself while also contributing to important research on CIPN.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 and over who suffer from chemotherapy-induced neuropathy (CIPN), according to the patient's report, more than 3 months since the end of the chemotherapy treatment.
• Exclusion Criteria:
• • 1. Sensory damage / neuropathy that existed even before the start of chemotherapy
• • 2. Incidents of recurrent falls even before the start of chemotherapy (over 2 falls for 6 months)
• • 3. Central nervous system involvement
• • 4. Major pre-morbid orthopedic lower limb impairment
• • 5. Hebrew language not sufficient for assessment and treatment